D-0924-2023 Class III Terminated

Recalled by SUN PHARMACEUTICAL INDUSTRIES INC — Princeton, NJ

FDA drug recall D-0924-2023 was initiated by SUN PHARMACEUTICAL INDUSTRIES INC on Jul 5, 2023 and is designated Class III. Reason for recall: Superpotent Drug: Out of Specification (OOS) results observed for unit dose content. The recall status is terminated (terminated Feb 26, 2024). Affected quantity: 20,884 cartons.

Recall details

Product Type
Drugs
Report Date
Jul 26, 2023
Initiation Date
Jul 5, 2023
Termination Date
Feb 26, 2024
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
20,884 cartons

Product description

Loteprednol Etabonate Ophthalmic Suspension, 5 mg/mL (0.5%), packaged as one bottle in a carton in a) 10 mL bottle (NDC# 62756-232-55) and b) 15 mL bottle (NDC # 62756-232-56), Rx only, Distributed by: Sun Pharmaceutical Ind., Inc., NJ 08512, Manufactured by: Sun Pharmaceutical Medicare Ltd., India.

Reason for recall

Superpotent Drug: Out of Specification (OOS) results observed for unit dose content.

Distribution pattern

USA nationwide.

Code information

Lot#: a) BAC0334A, Exp 06/2023; BAC0532A, Exp 11/2023 BAD0407A, Exp 08/2024 BAD0425A, Exp 08/2024; b) BAC0335A, Exp 06/2023, BAC0533A, Exp 10/2023, BAD0148A, Exp 03/2024, BAD0320A, Exp 07/2024

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0924-2023
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0924-2023. Report a data issue: hello@regdatalab.com.